National key project. Gastric disease vaccine with significant medical value, also known as Helicobacter pylori vaccine. Helicobacter pylori (Hp for short in English) is the main causative agent of chronic active gastritis, peptic ulcer, and gastric cancer. The vast majority of stomach diseases are caused by Helicobacter pylori. With the discovery of Helicobacter pylori, two Australian scientists won the 2005 Nobel Prize in Physiology or Medicine, opening up a new era of research on human digestive tract diseases. The prevention and treatment of gastric diseases caused by Helicobacter pylori is included in the World Health Organization's major research projects. The gastric disease vaccine developed by Chongqing Kangwei is a national Class I new biological product. It is a national key scientific research and industrialization project. It is included in the national “95” science and technology key research projects, the first batch of key topics in the field of biotechnology in the country's “15th Five-Year Plan” 863, the military's “95” medical and health research fund, the Chongqing Science and Technology Research Fund, key science and technology research projects and high-tech industrialization projects, and the 2002 Innovation Fund funded by the Ministry of Science and Technology. The company has completely independent intellectual property rights. It is the first and only vaccine approved for clinical trials in China. It is also the first gastric disease vaccine to enter phase III clinical trials internationally. This project has significant medical value. It is expected that it will be possible to obtain a national Class I new drug certificate within 2006. Venture capital entering the harvest phase of the gastric disease vaccine project has gone through laboratory research, small trials, and pilot trials. By July 2002, pre-clinical work was successfully completed. In October 2003, phase I and phase II clinical trials were officially launched. The test proved that the effective protection rate reached more than 90%, which was confirmed by the State Drug Administration. In June 2004, summary materials of phase I and phase II clinical trials and phase III trial plans were submitted to the State Drug Administration and accepted. In December 2005, the phase III clinical trial site work was completed. Samples are now being tested, and materials for the preparation of the new drug declaration are being prepared. It is expected that the new drug certificate will be obtained by the end of 2006. The company is ready for the industrialization of scientific research results. It is awaiting that the decision company commissioned China Pharmaceutical Group's Wuhan Pharmaceutical Design Institute to prepare and complete the project proposal in 2005, and also commissioned Sinopec Group Shanghai Engineering Co., Ltd. to prepare a project feasibility study report. It obtained 90,196.6 square meters of land use rights in the Sanzao Industrial Park in the Zhuhai National High-tech Industrial Zone, at a price of 900,000 yuan. In 2005, the project establishment, environmental assessment, factory planning and construction plan reporting in Zhuhai, site exploration, and design of complex buildings and terminal buildings were completed. A lot of preliminary preparations have been made for the industrialization of vaccines and drugs, and the board of directors is awaiting decision. Currently, mainly Sinopec's stock reform plan for the listed company it belongs to has not yet been decided, and the company's future main business needs to be repositioned. Leading the world and winning market opportunities, the gastric disease vaccine developed by Chongqing Kangwei is a national class I novel biological product. There are no similar products sold at home or abroad. It is the first gastric disease vaccine in the world to enter phase III clinical trials, and clinical trials are coming to an end. 2-3 years ahead of similar products abroad, 4-5 years ahead of domestic peers...